Compare AVTX & LPCV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AVTX | LPCV |
|---|---|---|
| Founded | 2011 | 2025 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 339.9M | 285.5M |
| IPO Year | 2015 | N/A |
| Metric | AVTX | LPCV |
|---|---|---|
| Price | $17.10 | $9.94 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $32.57 | N/A |
| AVG Volume (30 Days) | ★ 510.9K | 26.3K |
| Earning Date | 04-20-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 81.66 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $27,813,137.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2312.27 | N/A |
| 52 Week Low | $3.39 | $9.90 |
| 52 Week High | $20.72 | $10.03 |
| Indicator | AVTX | LPCV |
|---|---|---|
| Relative Strength Index (RSI) | 54.28 | 57.14 |
| Support Level | $15.36 | N/A |
| Resistance Level | $19.26 | $10.03 |
| Average True Range (ATR) | 1.36 | 0.00 |
| MACD | 0.07 | 0.00 |
| Stochastic Oscillator | 65.50 | 30.77 |
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
Launchpad Cadenza Acquisition Corp I is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities.